ArticleEuropean radiology2025
Rapid, moderate, or slow bleeding? CT analysis of abdominopelvic active vascular contrast extravasation classes and mortality outcomes.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable Knowledge-Guided Algorithm for Contrast Extravasation Detection on Computed Tomography.IEEE journal of translational engineering in health and medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBuilding on prior findings that active vascular contrast extravasation (AVCE) size is an independent predictor of in-hospital mortality in abdominopelvic hemorrhages, this study aimed to categorize AVCEs using latent profile analysis (LPA) and examine differences in patient characteristics, treatments, and outcomes.
methodsWe retrospectively included consecutive adults with CT-detected AVCE between January 2019 and May 2022. LPA was applied to classify AVCEs based on size-related features, optimizing the number of classes predictive of 24-h and in-hospital mortality. These classes were compared using univariable analysis with post-hoc pairwise comparisons to identify significant differences. Cutoff values for categorization were derived from size parameters and changes across arterial (AP) and portovenous (PVP) phases.
resultsLPA classified 223 patients with single-organ, traumatic, and nontraumatic AVCEs (mean age 59.8 ± 20.1 years, 123 men) into three groups-slow (n = 136), moderate (n = 75), and rapid (n = 12). Slow AVCEs showed smaller size parameters and minimal changes between AP and delayed phases. Rapid AVCEs frequently exhibited coexisting pseudoaneurysms, smaller areas on AP, lower mean attenuation differences in AP-PVP pairs, and were associated with lower systolic and diastolic blood pressures, requiring the highest quantity of packed red cells. Perimeter percentage changes between AP and PVP performed comparably to LPA classes and provided practical classification cutoffs.
conclusionLPA-based classification of AVCEs into slow, moderate, and rapid types revealed distinct size patterns and associated clinical outcomes, offering a robust framework for risk stratification and guiding management of abdominopelvic hemorrhages. KEY POINTS: Question It is unclear if the size of active vascular contrast extravasation (AVCE) is predictive of mortality in patients with abdominopelvic hemorrhage. Findings AVCEs could be classified by latent profile analysis into three groups: slow, moderate, and rapid, based on size at multiphasic CT with distinct mortality risks. Clinical relevance Practical cutoff values of perimeter percentage changes of AVCE between arterial- and portovenous-phase CT were identified for AVCE classification, potentially guiding clinical prioritization and management of patients with abdominopelvic hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.